Unfit individuals even have the alternative of venetoclax plus obinutuzumab (VO) as frontline therapy. This is based with a period III demo that in comparison VO with ClbO in elderly/unfit people.113 VO was top-quality in terms of response level and progression-free survival, and had a equivalent protection profile. During this https://sandrav864tbk2.azzablog.com/profile